FI122017B - Moniyksikköinen, tabletoitu annosmuoto - Google Patents

Moniyksikköinen, tabletoitu annosmuoto Download PDF

Info

Publication number: FI122017B
Authority: FI; Finland
Prior art keywords: dosage form; enteric; omeprazole; coating layer; coated
Prior art date: 1994-07-08

Application number

FI961057A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI961057L (fi

FI961057A0 (fi

Inventor

Kurt Ingmar Loevgren

Pontus John Arvid Bergstrand

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-08

Filing date

1996-03-07

Publication date

2011-07-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26662095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI122017(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-07-08 Priority claimed from SE9402433A external-priority patent/SE9402433D0/xx

1994-07-08 Priority claimed from SE9402432A external-priority patent/SE9402432D0/xx

1996-03-07 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

1996-03-07 Publication of FI961057A0 publication Critical patent/FI961057A0/fi

1996-03-29 Publication of FI961057L publication Critical patent/FI961057L/fi

2011-07-29 Application granted granted Critical

2011-07-29 Publication of FI122017B publication Critical patent/FI122017B/fi

Links

239000002552 dosage form Substances 0.000 title claims abstract description 55
239000010410 layer Substances 0.000 claims abstract description 136
239000002702 enteric coating Substances 0.000 claims abstract description 77
238000009505 enteric coating Methods 0.000 claims abstract description 77
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims abstract description 63
229960000381 omeprazole Drugs 0.000 claims abstract description 58
239000011162 core material Substances 0.000 claims abstract description 37
239000002253 acid Substances 0.000 claims abstract description 35
159000000011 group IA salts Chemical class 0.000 claims abstract description 9
239000008188 pellet Substances 0.000 claims description 93
239000000203 mixture Substances 0.000 claims description 33
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 31
238000000576 coating method Methods 0.000 claims description 27
150000001875 compounds Chemical class 0.000 claims description 26
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
239000011248 coating agent Substances 0.000 claims description 25
239000011247 coating layer Substances 0.000 claims description 17
239000000945 filler Substances 0.000 claims description 17
238000000034 method Methods 0.000 claims description 16
238000007906 compression Methods 0.000 claims description 14
230000006835 compression Effects 0.000 claims description 14
229920000642 polymer Polymers 0.000 claims description 13
230000008569 process Effects 0.000 claims description 11
239000013543 active substance Substances 0.000 claims description 7
159000000003 magnesium salts Chemical class 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
238000002156 mixing Methods 0.000 claims description 5
239000004014 plasticizer Substances 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 4
238000000634 powder X-ray diffraction Methods 0.000 claims description 4
239000000725 suspension Substances 0.000 claims description 4
230000007423 decrease Effects 0.000 claims description 3
SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims description 3
229960004770 esomeprazole Drugs 0.000 claims description 3
230000027119 gastric acid secretion Effects 0.000 claims description 3
208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
230000002757 inflammatory effect Effects 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
229910052760 oxygen Inorganic materials 0.000 claims 1
239000001301 oxygen Substances 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 abstract description 15
239000003826 tablet Substances 0.000 description 75
239000004480 active ingredient Substances 0.000 description 27
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
239000008213 purified water Substances 0.000 description 18
229920000168 Microcrystalline cellulose Polymers 0.000 description 17
239000008108 microcrystalline cellulose Substances 0.000 description 17
235000019813 microcrystalline cellulose Nutrition 0.000 description 17
229940016286 microcrystalline cellulose Drugs 0.000 description 17
238000009472 formulation Methods 0.000 description 14
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 13
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 12
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 12
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 12
239000000654 additive Substances 0.000 description 11
210000001035 gastrointestinal tract Anatomy 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
229940045902 sodium stearyl fumarate Drugs 0.000 description 11
239000000126 substance Substances 0.000 description 11
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 10
239000012530 fluid Substances 0.000 description 10
239000008187 granular material Substances 0.000 description 10
239000011777 magnesium Substances 0.000 description 10
239000000463 material Substances 0.000 description 10
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 9
239000001863 hydroxypropyl cellulose Substances 0.000 description 9
229940071676 hydroxypropylcellulose Drugs 0.000 description 9
230000000968 intestinal effect Effects 0.000 description 9
KWORUUGOSLYAGD-UHFFFAOYSA-N magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C.N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-UHFFFAOYSA-N 0.000 description 9
235000019359 magnesium stearate Nutrition 0.000 description 9
150000003839 salts Chemical class 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 8
230000002496 gastric effect Effects 0.000 description 8
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 8
238000009413 insulation Methods 0.000 description 8
229920003145 methacrylic acid copolymer Polymers 0.000 description 8
238000003756 stirring Methods 0.000 description 8
235000000346 sugar Nutrition 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 7
230000002378 acidificating effect Effects 0.000 description 7
150000001447 alkali salts Chemical class 0.000 description 7
230000000052 comparative effect Effects 0.000 description 7
229910052749 magnesium Inorganic materials 0.000 description 7
229940117841 methacrylic acid copolymer Drugs 0.000 description 7
230000003287 optical effect Effects 0.000 description 7
239000000454 talc Substances 0.000 description 7
229910052623 talc Inorganic materials 0.000 description 7
239000001069 triethyl citrate Substances 0.000 description 7
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 7
235000013769 triethyl citrate Nutrition 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
-1 benzimidazole compound Chemical class 0.000 description 6
239000011230 binding agent Substances 0.000 description 6
239000013078 crystal Substances 0.000 description 6
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 6
239000011824 nuclear material Substances 0.000 description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
239000006185 dispersion Substances 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
239000012452 mother liquor Substances 0.000 description 5
230000007935 neutral effect Effects 0.000 description 5
239000011734 sodium Substances 0.000 description 5
235000015424 sodium Nutrition 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
239000001692 EU approved anti-caking agent Substances 0.000 description 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
229920002301 cellulose acetate Polymers 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
239000000395 magnesium oxide Substances 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
239000000049 pigment Substances 0.000 description 4
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
229940068968 polysorbate 80 Drugs 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
239000000047 product Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000007891 compressed tablet Substances 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000000975 dye Substances 0.000 description 3
239000003974 emollient agent Substances 0.000 description 3
MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 3
239000002245 particle Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000011591 potassium Substances 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
235000019333 sodium laurylsulphate Nutrition 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
206010030216 Oesophagitis Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000002216 antistatic agent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
238000001479 atomic absorption spectroscopy Methods 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
235000011116 calcium hydroxide Nutrition 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229940081734 cellulose acetate phthalate Drugs 0.000 description 2
229920001688 coating polymer Polymers 0.000 description 2
229960000913 crospovidone Drugs 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
208000000718 duodenal ulcer Diseases 0.000 description 2
201000006549 dyspepsia Diseases 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
229960004667 ethyl cellulose Drugs 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
239000012535 impurity Substances 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
229960003174 lansoprazole Drugs 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
CRGZYKWWYNQGEC-UHFFFAOYSA-N magnesium;methanolate Chemical compound [Mg+2].[O-]C.[O-]C CRGZYKWWYNQGEC-UHFFFAOYSA-N 0.000 description 2
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
229960001855 mannitol Drugs 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
229960002900 methylcellulose Drugs 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000006174 pH buffer Substances 0.000 description 2
239000006179 pH buffering agent Substances 0.000 description 2
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
229950008882 polysorbate Drugs 0.000 description 2
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
239000004408 titanium dioxide Substances 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
230000036269 ulceration Effects 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
206010019375 Helicobacter infections Diseases 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
229910020038 Mg6Al2 Inorganic materials 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
229940008309 acetone / ethanol Drugs 0.000 description 1
239000000159 acid neutralizing agent Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
239000000956 alloy Substances 0.000 description 1
229910045601 alloy Inorganic materials 0.000 description 1
235000010210 aluminium Nutrition 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940024548 aluminum oxide Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
150000001556 benzimidazoles Chemical class 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000007931 coated granule Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000005056 compaction Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000000151 deposition Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
229940031954 dibutyl sebacate Drugs 0.000 description 1
239000007919 dispersible tablet Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
206010013864 duodenitis Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
208000006881 esophagitis Diseases 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000004088 foaming agent Substances 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
201000000052 gastrinoma Diseases 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000001879 gelation Methods 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000007542 hardness measurement Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical class [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
150000002681 magnesium compounds Chemical class 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical class [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
235000012254 magnesium hydroxide Nutrition 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
239000012528 membrane Substances 0.000 description 1
FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 1
238000000465 moulding Methods 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000008184 oral solid dosage form Substances 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
150000003021 phthalic acid derivatives Chemical class 0.000 description 1
229940068917 polyethylene glycols Drugs 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229940075065 polyvinyl acetate Drugs 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229940068984 polyvinyl alcohol Drugs 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000004080 punching Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000007581 slurry coating method Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
238000005563 spheronization Methods 0.000 description 1
238000009718 spray deposition Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Control Of El Displays (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Plant Substances (AREA)

FI961057A 1994-07-08 1996-03-07 Moniyksikköinen, tabletoitu annosmuoto FI122017B (fi)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
SE9402432		1994-07-08
SE9402433		1994-07-08
SE9402433A SE9402433D0 (sv)	1994-07-08	1994-07-08	New oral pharmaceutical dosage form
SE9402432A SE9402432D0 (sv)	1994-07-08	1994-07-08	New pharmaceutical dosage form
SE9500677		1995-06-07
PCT/SE1995/000677 WO1996001623A1 (fr)	1994-07-08	1995-06-07	Forme posologique sous forme de comprime composite (i)

Publications (3)

Publication Number	Publication Date
FI961057A0 FI961057A0 (fi)	1996-03-07
FI961057L FI961057L (fi)	1996-03-29
FI122017B true FI122017B (fi)	2011-07-29

Family

ID=26662095

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI961057A FI122017B (fi)	1994-07-08	1996-03-07	Moniyksikköinen, tabletoitu annosmuoto

Country Status (40)

Country	Link
US (1)	US5817338A (fr)
EP (2)	EP1078628B1 (fr)
JP (1)	JP3350054B2 (fr)
KR (1)	KR100384960B1 (fr)
CN (1)	CN1138534C (fr)
AT (2)	ATE414509T1 (fr)
AU (1)	AU695966B2 (fr)
BR (2)	BR9506018A (fr)
CA (1)	CA2170647C (fr)
CY (1)	CY2254B1 (fr)
CZ (1)	CZ289804B6 (fr)
DE (4)	DE69522921T2 (fr)
DK (2)	DK0723436T3 (fr)
DZ (1)	DZ1906A1 (fr)
EE (1)	EE03305B1 (fr)
ES (2)	ES2100142T3 (fr)
FI (1)	FI122017B (fr)
GR (1)	GR970300014T1 (fr)
HR (1)	HRP950349B1 (fr)
HU (1)	HUT75775A (fr)
IL (1)	IL114450A (fr)
IS (1)	IS4327A (fr)
MA (1)	MA23607A1 (fr)
MX (1)	MX9600857A (fr)
MY (1)	MY112915A (fr)
NO (1)	NO314125B3 (fr)
NZ (1)	NZ289948A (fr)
PL (1)	PL180395B1 (fr)
PT (2)	PT1078628E (fr)
RU (2)	RU2160094C2 (fr)
SA (1)	SA95160091B1 (fr)
SI (2)	SI0723436T1 (fr)
SK (1)	SK283626B6 (fr)
TN (1)	TNSN95075A1 (fr)
TR (1)	TR199500821A2 (fr)
TW (1)	TW450813B (fr)
UA (1)	UA41946C2 (fr)
WO (1)	WO1996001623A1 (fr)
YU (1)	YU49236B (fr)
ZA (1)	ZA955548B (fr)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9301830D0 (sv) *	1993-05-28	1993-05-28	Ab Astra	New compounds
US6875872B1 (en)	1993-05-28	2005-04-05	Astrazeneca	Compounds
DK0723436T3 (da) *	1994-07-08	2001-11-26	Astrazeneca Ab	Tabletteret flerenhedsdoseringsform
SE9402431D0 (sv) *	1994-07-08	1994-07-08	Astra Ab	New tablet formulation
SE9500422D0 (sv) *	1995-02-06	1995-02-06	Astra Ab	New oral pharmaceutical dosage forms
SE9500478D0 (sv) *	1995-02-09	1995-02-09	Astra Ab	New pharmaceutical formulation and process
US6279736B1 (en)	1995-04-19	2001-08-28	Capitol Specialty Plastics, Inc.	Barrier pack having an absorbing agent applied to the interior of the pack
ATE286394T1 (de)	1995-09-21	2005-01-15	Pharma Pass Ii Llc	Ein säurelabile omeprazol enthaltende arzneizusammensetzung und verfahren zu deren herstellung
US6489346B1 (en) *	1996-01-04	2002-12-03	The Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en)	1996-01-04	2004-03-02	The Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and methods of using same
US5840737A (en)	1996-01-04	1998-11-24	The Curators Of The University Of Missouri	Omeprazole solution and method for using same
US6645988B2 (en)	1996-01-04	2003-11-11	Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv)	1996-01-08	1996-01-08	Astra Ab	New oral pharmaceutical dosage forms
SE9600072D0 (sv) *	1996-01-08	1996-01-08	Astra Ab	New oral formulation of two active ingredients II
SE512835C2 (sv) *	1996-01-08	2000-05-22	Astrazeneca Ab	Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600071D0 (sv)	1996-01-08	1996-01-08	Astra Ab	New oral formulation of two active ingredients I
SE508669C2 (sv) *	1996-04-26	1998-10-26	Astra Ab	Nytt förfarande
SE9602442D0 (sv) *	1996-06-20	1996-06-20	Astra Ab	Administration of pharmaceuticals
US6623759B2 (en) *	1996-06-28	2003-09-23	Astrazeneca Ab	Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19637082A1 (de) *	1996-09-12	1998-03-19	Boehringer Mannheim Gmbh	Schnellzerfallende Pellets
WO1998019668A1 (fr) *	1996-11-06	1998-05-14	Sharmatek, Inc.	Mode d'administration differee de medicaments sensibles aux acides
SE510666C2 (sv) *	1996-12-20	1999-06-14	Astra Ab	Nya Kristallmodifikationer
WO1998030209A1 (fr) *	1997-01-06	1998-07-16	Pfizer Pharmaceuticals Inc.	Forme galenique pharmaceutique a liberation rapide et masquant le gout
IL131651A0 (en) *	1997-03-13	2001-01-28	Hexal Ag	A pharmaceutical formulation containing benzimidazoles with amino acid/caclodextrin combinations and a process for producing the same
SE9702000D0 (sv) *	1997-05-28	1997-05-28	Astra Ab	New pharmaceutical formulation
SE510650C2 (sv)	1997-05-30	1999-06-14	Astra Ab	Ny förening
US6747155B2 (en)	1997-05-30	2004-06-08	Astrazeneca Ab	Process
SE510643C2 (sv)	1997-06-27	1999-06-14	Astra Ab	Termodynamiskt stabil omeprazol natrium form B
SE9702533D0 (sv)	1997-07-01	1997-07-01	Astra Ab	New oral formulation
US6096340A (en)	1997-11-14	2000-08-01	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
US6174548B1 (en)	1998-08-28	2001-01-16	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
US6221402B1 (en)	1997-11-20	2001-04-24	Pfizer Inc.	Rapidly releasing and taste-masking pharmaceutical dosage form
IL136285A0 (en) *	1997-12-08	2001-05-20	Byk Gulden Lomberg Chem Fab	Pharmaceutical compositions containing an acid-labile active component
SE9704869D0 (sv) *	1997-12-22	1997-12-22	Astra Ab	New pharmaceutical formulaton II
SE9704870D0 (sv)	1997-12-22	1997-12-22	Astra Ab	New pharmaceutical formulation I
WO1999053918A1 (fr)	1998-04-20	1999-10-28	Eisai Co., Ltd.	Compositions stabilisees contenant des composes du type benzimidazole
DE69934505T2 (de) *	1998-05-18	2007-10-04	Takeda Pharmaceutical Co. Ltd.	Im munde zerfallende tablette enthaltend ein benzimidazole
ZA9810765B (en) *	1998-05-28	1999-08-06	Ranbaxy Lab Ltd	Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
US6733778B1 (en)	1999-08-27	2004-05-11	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
SE9803772D0 (sv)	1998-11-05	1998-11-05	Astra Ab	Pharmaceutical formulation
IL142703A (en) *	1998-11-10	2006-04-10	Astrazeneca Ab	Crystalline form of omeprazole
JP3926936B2 (ja)	1998-11-16	2007-06-06	エーザイ・アール・アンド・ディー・マネジメント株式会社	スルホキシド誘導体・アセトン錯体およびその製造法
SE9900274D0 (sv)	1999-01-28	1999-01-28	Astra Ab	New compound
ES2246238T3 (es)	1999-06-07	2006-02-16	Altana Pharma Ag	Nueva preparacion y forma de administracion que comprende un inhibidor de las bombas de protones labil en medio acido.
IL130602A0 (en) *	1999-06-22	2000-06-01	Dexcel Ltd	Stable benzimidazole formulation
US6245913B1 (en)	1999-06-30	2001-06-12	Wockhardt Europe Limited	Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6262086B1 (en)	1999-08-26	2001-07-17	Robert R. Whittle	Pharmaceutical unit dosage form
US6262085B1 (en)	1999-08-26	2001-07-17	Robert R. Whittle	Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en)	1999-08-26	2001-11-06	Robert R. Whittle	Method of improving bioavailability
US6780880B1 (en)	1999-08-26	2004-08-24	Robert R. Whittle	FT-Raman spectroscopic measurement
US6369087B1 (en)	1999-08-26	2002-04-09	Robert R. Whittle	Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en)	1999-08-26	2001-07-31	Robert R. Whittle	Dry blend pharmaceutical formulations
US6312723B1 (en)	1999-08-26	2001-11-06	Robert R. Whittle	Pharmaceutical unit dosage form
US6316020B1 (en)	1999-08-26	2001-11-13	Robert R. Whittle	Pharmaceutical formulations
US6326384B1 (en)	1999-08-26	2001-12-04	Robert R. Whittle	Dry blend pharmaceutical unit dosage form
SE0100823D0 (sv) *	2001-03-09	2001-03-09	Astrazeneca Ab	Method I to obtain microparticles
ES2168043B1 (es)	1999-09-13	2003-04-01	Esteve Labor Dr	Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
AU782538B2 (en)	1999-10-20	2005-08-04	Eisai Co. Ltd.	Method for stabilizing benzimidazole compounds
CA2290893C (fr)	1999-11-16	2007-05-01	Bernard Charles Sherman	Omeprazole de magnesium
EP1108425B1 (fr) *	1999-12-16	2005-06-08	Laboratorio Medinfar-Produtos Farmaceuticos, S.A.	Nouvelles préparations pharmaceutiques multi-unitaires stables contenant des benzimidazoles substitués
SE0000774D0 (sv)	2000-03-08	2000-03-08	Astrazeneca Ab	New formulation
US6544556B1 (en)	2000-09-11	2003-04-08	Andrx Corporation	Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US7147869B2 (en)	2000-12-07	2006-12-12	Altana Pharma Ag	Rapidly disintegrating tablet comprising an acid-labile active ingredient
US20020192299A1 (en) *	2000-12-28	2002-12-19	Rajneesh Taneja	Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
SE0100822D0 (sv) *	2001-03-09	2001-03-09	Astrazeneca Ab	Method II to obtain microparticles
CA2448927C (fr) *	2001-05-30	2011-08-09	Euro-Celtique, S.A.	Composition pharmaceutique
US8206741B2 (en)	2001-06-01	2012-06-26	Pozen Inc.	Pharmaceutical compositions for the coordinated delivery of NSAIDs
AU2002316020B2 (en) *	2001-07-16	2007-03-15	Astrazeneca Ab	Pharmaceutical formulation comprising a proton pump inhibitor and antacids
SE0102993D0 (sv)	2001-09-07	2001-09-07	Astrazeneca Ab	New self emulsifying drug delivery system
NZ532096A (en)	2001-09-28	2006-10-27	Mcneil Ppc Inc	Dosage forms having an inner core and outer shell with different shapes
ES2198195B1 (es) *	2001-12-18	2004-10-01	Laboratorios Del Dr. Esteve, S.A.	Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
WO2003063840A2 (fr) *	2002-01-25	2003-08-07	Santarus, Inc.	Administration par voie muqueuse d'inhibiteurs de la pompe a protons
ES2286408T3 (es)	2002-03-05	2007-12-01	Astrazeneca Ab	Sales de alquilamonio de omeprazol e esomeprazol.
US20040082618A1 (en) *	2002-07-03	2004-04-29	Rajneesh Taneja	Liquid dosage forms of acid labile drugs
RU2332237C2 (ru) *	2002-08-02	2008-08-27	Рациофарм Гмбх	Фармацевтический препарат, содержащий производное бензимидазола, смешанное с микрокристаллической целлюлозой, и способ его изготовления
MY148805A (en) *	2002-10-16	2013-05-31	Takeda Pharmaceutical	Controlled release preparation
US20040162263A1 (en) *	2002-10-31	2004-08-19	Supergen, Inc., A Delaware Corporation	Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
US20040242642A1 (en) *	2002-11-18	2004-12-02	Dr. Reddy's Laboratories Limited	Crystalline esomeprazole compounds and process for the preparation thereof
US9107804B2 (en)	2002-12-10	2015-08-18	Nortec Development Associates, Inc.	Method of preparing biologically active formulations
US20040121004A1 (en) *	2002-12-20	2004-06-24	Rajneesh Taneja	Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) *	2002-12-20	2007-10-18	Rajneesh Taneja	Dosage Forms Containing A PPI, NSAID, and Buffer
WO2004066924A2 (fr) *	2003-01-24	2004-08-12	Andrx Labs Llc	Nouvelle formulation pharmaceutique contenant un inhibiteur de pompe a proton et un antiacide
US20040185119A1 (en) *	2003-02-26	2004-09-23	Theuer Richard C.	Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency
PE20050150A1 (es)	2003-05-08	2005-03-22	Altana Pharma Ag	Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es)	2003-05-08	2005-03-04	Altana Pharma Ag	Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
US8802139B2 (en)	2003-06-26	2014-08-12	Intellipharmaceutics Corp.	Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EP1646404B1 (fr) *	2003-07-11	2010-01-13	AstraZeneca AB	Composition solide comprenant un inhibiteur de la pompe a protons
US8993599B2 (en)	2003-07-18	2015-03-31	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050043359A1 (en) *	2003-08-20	2005-02-24	The Procter & Gamble Company	Kit for treatment of upper gastrointestinal tract conditions
WO2005020954A2 (fr) *	2003-09-03	2005-03-10	Agi Therapeutics Limited	Formulations inhibitrices de pompe a proton, et procedes d'elaboration et d'utilisation correspondantes
TWI372066B (en)	2003-10-01	2012-09-11	Wyeth Corp	Pantoprazole multiparticulate formulations
RU2257890C2 (ru) *	2003-10-06	2005-08-10	Марио Атилио Лос	Способ получения устойчивых фармацевтических композиций в форме таблеток, содержащих омепразол, и фармацевтические композиции, полученные таким способом
WO2005046634A2 (fr) *	2003-11-14	2005-05-26	Siegfried Generics International Ag	Forme galenique resistant au suc gastrique
US8815916B2 (en)	2004-05-25	2014-08-26	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en)	2004-05-25	2014-12-09	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1753405A4 (fr) *	2004-06-10	2008-09-17	Glatt Air Tech Inc	Preparation pharmaceutique a liberation lente
JP2008502740A (ja) *	2004-06-15	2008-01-31	テバファーマシューティカルインダストリーズリミティド	ベンズイミダゾール化合物の安定医薬製剤
US8461187B2 (en)	2004-06-16	2013-06-11	Takeda Pharmaceuticals U.S.A., Inc.	Multiple PPI dosage form
US20050281876A1 (en)	2004-06-18	2005-12-22	Shun-Por Li	Solid dosage form for acid-labile active ingredient
PL1916994T3 (pl) *	2004-06-29	2014-05-30	Takeda Pharma As	Wytwarzanie kompozycji farmaceutycznej o szybkim uwalnianiu leków nierozpuszczalnych w wodzie i kompozycje farmaceutyczne otrzymywane sposobem według wynalazku
US8394409B2 (en)	2004-07-01	2013-03-12	Intellipharmaceutics Corp.	Controlled extended drug release technology
ES2246149B1 (es) *	2004-07-02	2007-06-01	Esteve Quimica, S.A.	Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
EP1621187A1 (fr) *	2004-07-26	2006-02-01	AstraZeneca AB	Formulations pharmaceutiques de comprimés multiparticulaires et procédé de préparation
US20060024362A1 (en) *	2004-07-29	2006-02-02	Pawan Seth	Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en)	2004-08-23	2020-04-21	Intellipharmaceutics Corp	Controlled release composition using transition coating, and method of preparing same
US8715724B2 (en) *	2004-10-29	2014-05-06	Mayne Pharma International Pty Ltd	Tabletting process
GB0427455D0 (en) *	2004-12-15	2005-01-19	Jagotec Ag	Dosage forms
WO2006066932A1 (fr) *	2004-12-24	2006-06-29	Lek Pharmaceuticals D.D.	Composition pharmaceutique stable comprenant une substance active sous la forme d’une solution solide
US8673352B2 (en)	2005-04-15	2014-03-18	Mcneil-Ppc, Inc.	Modified release dosage form
WO2007008305A1 (fr) *	2005-07-08	2007-01-18	Cherng-Ju Kim	Comprime a revetement asymetrique
ES2278511B1 (es) *	2005-07-28	2008-06-16	Laboratorios Almirall S.A.	Comprimidos con perfil de disolucion mejorado.
US20060165776A1 (en) *	2005-08-31	2006-07-27	Ramesh Sesha	Antidepressant oral pharmaceutical compositions
US9440003B2 (en) *	2005-11-04	2016-09-13	Boston Scientific Scimed, Inc.	Medical devices having particle-containing regions with diamond-like coatings
AR057181A1 (es) *	2005-11-30	2007-11-21	Astra Ab	Nueva forma de dosificacion de combinacion
KR20080076924A (ko)	2005-12-05	2008-08-20	아스트라제네카 아베	에소메프라졸 비-염 형태의 제조를 위한 신규 방법
US20070141151A1 (en) *	2005-12-20	2007-06-21	Silver David I	Lansoprazole orally disintegrating tablets
US10064828B1 (en)	2005-12-23	2018-09-04	Intellipharmaceutics Corp.	Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5457830B2 (ja)	2006-04-03	2014-04-02	オディディ，イサ	オルガノゾル被膜を含む制御放出送達デバイス
KR101784001B1 (ko)	2006-04-04	2017-10-23	케이지 액퀴지션 엘엘씨	항혈소판제와 산 억제제를 포함하는 경구 투여용 약학 조성물
US20090068263A1 (en) *	2006-04-20	2009-03-12	Themis Laboratories Private Limited	Multiple unit compositions
US10960077B2 (en)	2006-05-12	2021-03-30	Intellipharmaceutics Corp.	Abuse and alcohol resistant drug composition
US9023400B2 (en) *	2006-05-24	2015-05-05	Flamel Technologies	Prolonged-release multimicroparticulate oral pharmaceutical form
CA2654402A1 (fr) *	2006-06-01	2007-12-06	Adel Penhasi	Formulation pharmaceutique comprenant des unites multiples
US7713549B2 (en) *	2006-06-30	2010-05-11	Board Of Trustees Of The University Of Arkansas	Extended release perforated tablet
EP2081546A2 (fr) *	2006-10-17	2009-07-29	Ranbaxy Laboratories Limited	Composition de comprimés à multiples unités de composés de benzimidazole
CA2667682A1 (fr)	2006-10-27	2008-05-15	The Curators Of The University Of Missouri	Compositions comprenant des agents d'inhibition de la pompe a protons labiles d'acide, au moins un autre agent pharmaceutiquement actif et leurs procedes d'utilisation
US8352042B2 (en) *	2006-11-28	2013-01-08	The Alfred E. Mann Foundation For Scientific Research	Remote controls and ambulatory medical systems including the same
US20080194307A1 (en) *	2007-02-13	2008-08-14	Jeff Sanger	Sports-based game of chance
WO2009049160A1 (fr)	2007-10-12	2009-04-16	Takeda Pharmaceuticals North America	Procédés de traitement de troubles gastro-intestinaux indépendants de la prise alimentaire
JP2011512416A (ja)	2008-02-20	2011-04-21	ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ	オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法
EP2293782B1 (fr)	2008-05-06	2015-08-12	Dexcel Pharma Technologies Ltd.	Formule stable de benzimidazole
DE102008045339A1 (de)	2008-09-01	2010-03-04	Stada Arzneimittel Ag	Pharmazeutisches Pellet
US9220698B2 (en)	2008-09-09	2015-12-29	Pozen Inc.	Method for delivering a pharmaceutical composition to patient in need thereof
US8828953B2 (en)	2009-04-20	2014-09-09	NaZura BioHealth, Inc.	Chemosensory receptor ligand-based therapies
US9901551B2 (en)	2009-04-20	2018-02-27	Ambra Bioscience Llc	Chemosensory receptor ligand-based therapies
KR20120030106A (ko)	2009-06-25	2012-03-27	아스트라제네카 아베	Ｎｓａｉｄ-연관된 궤양의 발생 위험이 있는 환자의 치료 방법
WO2011080502A2 (fr)	2009-12-29	2011-07-07	Orexo Ab	Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
US20120294937A1 (en)	2009-12-29	2012-11-22	Novartis Ag	New pharmaceutical dosage form for the treatment of gastric acid-related disorders
FR2959509B1 (fr)	2010-05-03	2012-07-13	Prod Chim Auxiliaires Et De Synthese	Phase precurseur et son utilisation pour preparer le sel de magnesium tetrahydrate d'un enantiomere d'omeprazole
WO2011144975A1 (fr) *	2010-05-15	2011-11-24	Jubilant Life Sciences Limited	Compositions multi-unités
IT1401284B1 (it)	2010-08-06	2013-07-18	Valpharma S P A	Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
MX2013004364A (es)	2010-10-19	2013-07-02	Elcelyx Therapeutics Inc	Terapias a base de ligando del receptor quimiosensorial.
HK1201477A1 (en) *	2011-11-02	2015-09-04	Laboratorios Del. Dr. Esteve, S.A.	Pharmaceutical composition of omeprazole
EP2797600A4 (fr)	2011-12-28	2015-09-16	Pozen Inc	Compositions et procédés d'administration d'oméprazole plus acide acétylsalicylique améliorés
CN103040774B (zh) *	2012-11-30	2015-03-04	上海信谊万象药业股份有限公司	埃索美拉唑镁肠溶片中埃索美拉唑镁的制粒包衣工艺
CN103044400A (zh) *	2012-12-21	2013-04-17	北京华禧联合科技发展有限公司	埃索美拉唑镁盐及其制备方法
WO2014136494A1 (fr) *	2013-03-08	2014-09-12	富士フイルム株式会社	Fine particule à enrobage gastro-résistant et composition de médicament
WO2015155307A1 (fr)	2014-04-11	2015-10-15	Sanovel Ilac Sanayi Ve Ticaret A.S.	Combinaisons pharmaceutiques de rivaroxaban et d'inhibiteurs de pompe à protons
US10130618B2 (en)	2014-04-11	2018-11-20	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2016057744A1 (fr) *	2014-10-08	2016-04-14	Synthetic Biologics, Inc.	Formulations de bêta-lactamase et utilisations de celles-ci
US20170182070A1 (en)	2014-10-08	2017-06-29	Mayne Pharma International Pty Ltd.	Controlled Release Doxycycline
CN104586809A (zh) *	2015-01-08	2015-05-06	浙江亚太药业股份有限公司	一种埃索美拉唑镁微丸肠溶片及制备方法
US11103517B2 (en)	2015-04-07	2021-08-31	Dr. Reddy's Laboratories Ltd.	Pharmaceutical compositions for minocycline
US20170042806A1 (en)	2015-04-29	2017-02-16	Dexcel Pharma Technologies Ltd.	Orally disintegrating compositions
US10076494B2 (en)	2016-06-16	2018-09-18	Dexcel Pharma Technologies Ltd.	Stable orally disintegrating pharmaceutical compositions
US10137111B2 (en)	2016-08-11	2018-11-27	Adamis Pharmaceuticals Corporation	Drug compositions comprising an anti-parasitic and proton pump inhibitor
US10946002B2 (en) *	2016-10-06	2021-03-16	Jubilant Generics Limited	Pharmaceutical suspension dosage form of benzimidazole compounds and process of preparation thereof
KR101877350B1 (ko)	2016-10-28	2018-08-09	한미약품 주식회사	에스오메프라졸 함유 복합 캡슐제 및 그 제조방법
CZ2017315A3 (cs)	2017-06-02	2018-12-12	Zentiva, K.S.	Dávkovací jednotka s PPI (inhibitory protonové pumpy)
WO2019113493A1 (fr)	2017-12-08	2019-06-13	Adamis Pharmaceuticals Corporation	Compositions de médicaments
KR102080023B1 (ko)	2018-01-29	2020-02-21	주식회사 종근당	에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko)	2018-01-29	2019-10-08	주식회사 종근당	에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
US12251375B2 (en)	2018-08-23	2025-03-18	Chong Kun Dang Pharmaceutical Corp.	Pharmaceutical preparation having excellent dissolution properties, containing esomeprazole and sodium bicarbonate
WO2021020771A1 (fr)	2019-07-26	2021-02-04	주식회사 종근당	Composition pharmaceutique stable comprenant de l'ésoméprazole et du bicarbonate de sodium
US20230058473A1 (en)	2020-01-27	2023-02-23	Towa Pharmaceutical Co., Ltd.	Esomeprazole oral preparation and method for producing the same
KR102573842B1 (ko)	2020-02-21	2023-09-01	주식회사 종근당	방출특성이 우수한 에스오메프라졸 및 탄산수소나트륨의 약제학적 조성물
KR20210012881A (ko)	2020-02-28	2021-02-03	주식회사 종근당	에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
CN114569579B (zh)	2020-12-02	2023-10-31	丽珠医药集团股份有限公司	肠溶微丸、其制备方法和包含它的制剂
CN115120569B (zh) *	2022-07-07	2023-11-28	江苏中邦制药有限公司	一种去除微丸间静电的方法
KR20240030479A (ko)	2022-08-31	2024-03-07	한올바이오파마주식회사	에스오메프라졸 및 제산제를 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7804231L (sv) *	1978-04-14	1979-10-15	Haessle Ab	Magsyrasekretionsmedel
JPS5535031A (en) *	1978-09-04	1980-03-11	Shin Etsu Chem Co Ltd	Enteric coating composition
JPS5598120A (en) *	1979-01-16	1980-07-25	Shin Etsu Chem Co Ltd	Preparation of drug having enteric coating
FR2471186A1 (fr) *	1979-12-10	1981-06-19	Roussel Uclaf	Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4340582A (en) *	1981-01-15	1982-07-20	Abbott Laboratories	Erythromycin base tablets
US4377568A (en) *	1981-08-12	1983-03-22	Merck Sharp & Dohme (I.A.) Corp.	Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) *	1981-11-20	1987-05-25	Benzon As Alfred	Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS5973529A (ja) *	1982-10-12	1984-04-25	Sankyo Co Ltd	被覆固形製剤の製造法
US4525339A (en) *	1982-10-15	1985-06-25	Hoffmann-La Roche Inc.	Enteric coated oral dosage form
US4518433A (en) *	1982-11-08	1985-05-21	Fmc Corporation	Enteric coating for pharmaceutical dosage forms
GB2132887A (en) *	1982-11-15	1984-07-18	Procter & Gamble	Enteric-coated anti-inflammatory compositions
SE8301182D0 (sv) *	1983-03-04	1983-03-04	Haessle Ab	Novel compounds
US4556552A (en) *	1983-09-19	1985-12-03	Colorcon, Inc.	Enteric film-coating compositions
AU571312B2 (en) *	1984-02-10	1988-04-14	Nycomed Danmark A/S	Diffusion coated multiple-units dosage form
US4568560A (en) *	1984-03-16	1986-02-04	Warner-Lambert Company	Encapsulated fragrances and flavors and process therefor
DE3524337A1 (de) *	1985-07-08	1987-01-08	Roehm Gmbh	Arzneimittelumhuellung
SE450087B (sv) *	1985-10-11	1987-06-09	Haessle Ab	Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
GB2189699A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated acid-labile medicaments
GB2189698A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated omeprazole tablets
US4759749A (en) *	1986-05-27	1988-07-26	Level 1 Technologies, Inc.	Heater for physiological fluids
GB8630080D0 (en) *	1986-12-17	1987-01-28	Glaxo Group Ltd	Medicaments
SE8803822D0 (sv) *	1988-10-26	1988-10-26		Novel dosage form
SE8804629D0 (sv) *	1988-12-22	1988-12-22	Ab Haessle	New therapeutically active compounds
US5026559A (en) *	1989-04-03	1991-06-25	Kinaform Technology, Inc.	Sustained-release pharmaceutical preparation
US5041430A (en) *	1989-09-18	1991-08-20	Du Pont Mereck Pharmaceutical Company	Oral anticoagulant/platelet inhibitor low dose formulation
WO1991019712A1 (fr) *	1990-06-20	1991-12-26	Aktiebolaget Astra	Derives de dialcoxy-pyridinyle-benzimidazole, procede de preparation et utilisation pharmaceutique de ces derives
YU48263B (sh) *	1991-06-17	1997-09-30	Byk Gulden Lomberg Chemische Fabrik Gmbh.	Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
DK0519144T3 (da) *	1991-06-21	1998-03-23	Ilsan Ilac Ve Hammaddeleri San	Ny galenisk proces for omeprazol indeholdende pellets
JP3142919B2 (ja) *	1991-11-06	2001-03-07	旭化成株式会社	セルロース誘導体ラテックス及びその製法
US5160742A (en) *	1991-12-31	1992-11-03	Abbott Laboratories	System for delivering an active substance for sustained release
EP0653935B1 (fr) *	1992-08-05	2002-05-08	F.H. FAULDING & CO. LIMITED	Composition pharmaceutique sous forme de granules
US5330759A (en) *	1992-08-26	1994-07-19	Sterling Winthrop Inc.	Enteric coated soft capsules and method of preparation thereof
SE9301830D0 (sv) *	1993-05-28	1993-05-28	Ab Astra	New compounds
SE9302396D0 (sv) *	1993-07-09	1993-07-09	Ab Astra	A novel compound form
SE9302395D0 (sv) *	1993-07-09	1993-07-09	Ab Astra	New pharmaceutical formulation
JP3017906B2 (ja) *	1993-10-08	2000-03-13	信越化学工業株式会社	腸溶性コーティング剤分散液
DK0723777T3 (da) *	1993-10-12	2002-10-28	Mitsubishi Pharma Corp	Tablet indeholdende enteriske granuler
GB2285989A (en) *	1994-01-28	1995-08-02	Merck Frosst Canada Inc	Aqueous formulations for enteric coatings
SE9402431D0 (sv) *	1994-07-08	1994-07-08	Astra Ab	New tablet formulation
DK0723436T3 (da) *	1994-07-08	2001-11-26	Astrazeneca Ab	Tabletteret flerenhedsdoseringsform

1995
- 1995-06-07 DK DK95926054T patent/DK0723436T3/da active
- 1995-06-07 PT PT00117629T patent/PT1078628E/pt unknown
- 1995-06-07 RU RU96107115/14A patent/RU2160094C2/ru not_active IP Right Cessation
- 1995-06-07 JP JP50424896A patent/JP3350054B2/ja not_active Expired - Lifetime
- 1995-06-07 EP EP00117629A patent/EP1078628B1/fr not_active Revoked
- 1995-06-07 DK DK00117629T patent/DK1078628T3/da active
- 1995-06-07 MX MX9600857A patent/MX9600857A/es unknown
- 1995-06-07 SI SI9530541T patent/SI0723436T1/xx unknown
- 1995-06-07 NZ NZ289948A patent/NZ289948A/en not_active IP Right Cessation
- 1995-06-07 EE EE9600035A patent/EE03305B1/xx unknown
- 1995-06-07 PL PL95313387A patent/PL180395B1/pl unknown
- 1995-06-07 PT PT95926054T patent/PT723436E/pt unknown
- 1995-06-07 CZ CZ1996732A patent/CZ289804B6/cs not_active IP Right Cessation
- 1995-06-07 UA UA96030835A patent/UA41946C2/uk unknown
- 1995-06-07 DE DE69522921T patent/DE69522921T2/de not_active Revoked
- 1995-06-07 HU HU9600573A patent/HUT75775A/hu not_active Application Discontinuation
- 1995-06-07 BR BR9506018A patent/BR9506018A/pt not_active Application Discontinuation
- 1995-06-07 ES ES95926054T patent/ES2100142T3/es not_active Expired - Lifetime
- 1995-06-07 AU AU29937/95A patent/AU695966B2/en not_active Expired
- 1995-06-07 US US08/454,395 patent/US5817338A/en not_active Expired - Lifetime
- 1995-06-07 ES ES00117629T patent/ES2316333T3/es not_active Expired - Lifetime
- 1995-06-07 SI SI9530733T patent/SI1078628T1/sl unknown
- 1995-06-07 RU RU96107115/15K patent/RU2531553C2/ru not_active IP Right Cessation
- 1995-06-07 AT AT00117629T patent/ATE414509T1/de active
- 1995-06-07 DE DE29522419U patent/DE29522419U1/de not_active Expired - Lifetime
- 1995-06-07 CA CA002170647A patent/CA2170647C/fr not_active Expired - Lifetime
- 1995-06-07 SK SK301-96A patent/SK283626B6/sk not_active IP Right Cessation
- 1995-06-07 KR KR1019960701156A patent/KR100384960B1/ko not_active Expired - Lifetime
- 1995-06-07 WO PCT/SE1995/000677 patent/WO1996001623A1/fr not_active Ceased
- 1995-06-07 EP EP95926054A patent/EP0723436B1/fr not_active Revoked
- 1995-06-07 DE DE69535889T patent/DE69535889D1/de not_active Expired - Lifetime
- 1995-06-07 AT AT95926054T patent/ATE206044T1/de not_active IP Right Cessation
- 1995-06-07 CN CNB951908154A patent/CN1138534C/zh not_active Expired - Lifetime
- 1995-06-07 DE DE0723436T patent/DE723436T1/de active Pending
- 1995-06-15 TW TW084106117A patent/TW450813B/zh not_active IP Right Cessation
- 1995-06-20 HR HR950349A patent/HRP950349B1/xx not_active IP Right Cessation
- 1995-07-04 ZA ZA955548A patent/ZA955548B/xx unknown
- 1995-07-04 DZ DZ950083A patent/DZ1906A1/fr active
- 1995-07-04 IL IL11445095A patent/IL114450A/xx not_active IP Right Cessation
- 1995-07-05 YU YU44895A patent/YU49236B/sh unknown
- 1995-07-06 TR TR95/00821A patent/TR199500821A2/xx unknown
- 1995-07-06 MA MA23946A patent/MA23607A1/fr unknown
- 1995-07-07 TN TNTNSN95075A patent/TNSN95075A1/fr unknown
- 1995-07-08 MY MYPI95001919A patent/MY112915A/en unknown
- 1995-07-09 SA SA95160091A patent/SA95160091B1/ar unknown
1996
- 1996-03-04 IS IS4327A patent/IS4327A/is unknown
- 1996-03-07 NO NO19960950A patent/NO314125B3/no not_active IP Right Cessation
- 1996-03-07 FI FI961057A patent/FI122017B/fi not_active IP Right Cessation
1997
- 1997-05-06 BR BR1100458-4A patent/BR1100458A/pt active IP Right Review Request
- 1997-05-30 GR GR970300014T patent/GR970300014T1/el unknown
2001
- 2001-12-17 CY CY0100048A patent/CY2254B1/xx unknown

Also Published As

Publication number	Publication date
YU44895A (sh)	1998-07-10
CA2170647A1 (fr)	1996-01-25
ATE414509T1 (de)	2008-12-15
CZ73296A3 (en)	1996-07-17
MX9600857A (es)	1997-06-28
TR199500821A2 (tr)	1996-06-21
EP1078628A2 (fr)	2001-02-28
DK0723436T3 (da)	2001-11-26
EP1078628B1 (fr)	2008-11-19
EE03305B1 (et)	2000-12-15
DZ1906A1 (fr)	2002-02-17
HUT75775A (en)	1997-05-28
KR100384960B1 (ko)	2003-08-21
DE69522921D1 (de)	2001-10-31
IS4327A (is)	1996-03-04
HRP950349B1 (en)	2002-06-30
CZ289804B6 (cs)	2002-04-17
NZ289948A (en)	1997-07-27
NO314125B1 (no)	2003-02-03
SA95160091B1 (ar)	2005-06-14
ES2316333T3 (es)	2009-04-16
ZA955548B (en)	1996-01-08
SK30196A3 (en)	1997-09-10
YU49236B (sh)	2004-12-31
RU2531553C2 (ru)	2014-10-20
BR9506018A (pt)	1997-09-02
JP3350054B2 (ja)	2002-11-25
EP1078628A3 (fr)	2003-03-19
AU695966B2 (en)	1998-08-27
NO960950L (no)	1996-03-07
IL114450A (en)	1999-09-22
CY2254B1 (en)	2003-07-04
JPH09502739A (ja)	1997-03-18
SI1078628T1 (sl)	2009-04-30
EP0723436B1 (fr)	2001-09-26
ES2100142T3 (es)	2002-03-01
MY112915A (en)	2001-10-31
HK1008300A1 (en)	1999-05-07
TW450813B (en)	2001-08-21
PL180395B1 (pl)	2001-01-31
PT1078628E (pt)	2009-01-27
CN1138534C (zh)	2004-02-18
ES2100142T1 (es)	1997-06-16
DE69535889D1 (de)	2009-01-02
NO960950D0 (no)	1996-03-07
AU2993795A (en)	1996-02-09
DE29522419U1 (de)	2003-07-03
ATE206044T1 (de)	2001-10-15
WO1996001623A1 (fr)	1996-01-25
HU9600573D0 (en)	1996-05-28
SI0723436T1 (en)	2002-02-28
HRP950349A2 (en)	1997-06-30
FI961057L (fi)	1996-03-29
PT723436E (pt)	2002-02-28
NO314125B3 (no)	2008-12-08
UA41946C2 (uk)	2001-10-15
GR970300014T1 (en)	1997-05-31
DE69522921T2 (de)	2002-04-11
SK283626B6 (sk)	2003-10-07
IL114450A0 (en)	1995-11-27
FI961057A0 (fi)	1996-03-07
EP0723436A1 (fr)	1996-07-31
BR1100458A (pt)	2005-05-03
RU2160094C2 (ru)	2000-12-10
CN1134666A (zh)	1996-10-30
US5817338A (en)	1998-10-06
MA23607A1 (fr)	1996-04-01
DE723436T1 (de)	1997-09-11
CA2170647C (fr)	2001-03-13
TNSN95075A1 (fr)	1996-02-06
DK1078628T3 (da)	2009-02-23
PL313387A1 (en)	1996-06-24

Legal Events

Date

Code

Title

Description

2009-04-17

PC

Transfer of assignment of patent

Owner name: ASTRAZENECA AB

Free format text: ASTRAZENECA AB